Navigation Links
New malaria vaccine shows promise in early clinical trial

A malaria vaccine remains the most desired tool to combat the worsening malaria epidemic in many developing countries. Pierre Druilhe and colleagues (from the Institut Pasteur in Paris) have completed the first human trial of a vaccine based on MSP3, a protein present on the surface of the malaria parasite, with very encouraging results.

As the researchers report in the international open-access medical journal PLoS Medicine, most of the 30 healthy volunteers who received the vaccine developed strong, specific, and in some cases long-lasting immune responses against the MSP3 protein.

However, as researchers have learned from many early HIV and malaria vaccine trials, the crucial question is whether these immune responses mean that vaccinated people are actually protected against malaria. The straightforward way to test this is to expose the vaccinated trial participants to malaria and see if they are protected. However, this risky test is not ethical during the early stages of vaccine testing.

But Druilhe and colleagues were nevertheless able to take their early trial a step further: They demonstrated that antibodies from the blood of vaccinated volunteers were able to inhibit growth of the malaria parasite in two independent laboratory assays.

"A particular strength of the MSP3 trial is that functional assays [tests to see whether the vaccine could kill parasites] were utilized to assess the quality of the antibody response produced," say Brendan Crabb and James Beeson in an accompanying Perspective. However, they also point out that important questions remain, some of which will only be answered in additional clinical trials. Based on the results described in the PLoS Medicine article, Druilhe and colleagues have started a Phase II efficacy field trial of the MSP3 vaccine in malaria-exposed individuals.


'"/>

Source:Public Library of Science


Page: 1

Related biology news :

1. Scientists reveal molecular secrets of the malaria parasite
2. Simple drug has the potential to save many lives threatened by malaria
3. Molecular models advance the fight against malaria
4. Reducing malarial transmission in Africa
5. Sickle cell and protection against malaria
6. Chemists synthesize molecule that helps body battle cancers, malaria
7. Gene expands malarias invasion options
8. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
9. Measuring hidden parasites in falciparum malaria
10. Old drug, new tricks: Prospects for slashing the impact of malaria
11. Researchers discover how malaria parasite disperses from red blood cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New malaria vaccine shows promise early clinical trial

(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... cancer as a major cause of death among children ... adequately addressed by national or international health organizations and ... Hospital. This growing rate of pediatric cancer is occurring ... is being reduced through the efforts of the World ...
... prices at the gas pump could come in the ... biomass, according to a joint feasibility study for the ... Oak Ridge National Laboratory report outlines a national strategy ... organic matter that is available on a renewable or ...
... everything was big has helped Queensland researchers to unearth ... responsible for wiping out Australian giant marsupials or megafauna ... specimens' such as giant kangaroos and wombats, the researchers ... performed the first systematic analysis of a site in ...
Cached Biology News:Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3Human Cells Filmed Instantly Messaging for First Time 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... , ... August 26, 2015 , ... PRC Clinical, ... develop new business relationships with local sponsors in southern California. The Clinical Trial Management ... drug development processes and regulatory pathways., , Stem Cell ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Multiple Ultrasound Solution Provider Doubles Sales Over Same Period Last ... ... WAUKESHA, Wis., Aug. 27 MedPro Imaging, a premier,provider of ... representing a doubling of sales,over the same period last year. Recent ...
... Following the successful acquisition of,Drug Development Solutions (,DDS,) ... today that it has fully,integrated its two early ... Early Phase., Chiltern Early Phase is providing ... via its two well established units in Slough,(just ...
... Inc. (Nasdaq: AMLN ) and Eli Lilly and ... provided context and additional information,regarding the August 18, 2008 ... alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies were ... well as others, and previously reported these cases to ...
Cached Biology Technology:MedPro Installs 1000th Ultrasound System Worldwide 2Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: